296 related articles for article (PubMed ID: 16045558)
1. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
2. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
3. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
[TBL] [Abstract][Full Text] [Related]
4. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer.
Papadopoulos I; Sivridis E; Giatromanolaki A; Koukourakis MI
Clin Cancer Res; 2001 Jun; 7(6):1533-8. PubMed ID: 11410487
[TBL] [Abstract][Full Text] [Related]
5. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients.
Fujita K; Denda K; Yamamoto M; Matsumoto T; Fujime M; Irimura T
Br J Cancer; 1999 Apr; 80(1-2):301-8. PubMed ID: 10390012
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
7. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer.
Ricciardelli C; Mayne K; Sykes PJ; Raymond WA; McCaul K; Marshall VR; Horsfall DJ
Clin Cancer Res; 1998 Apr; 4(4):963-71. PubMed ID: 9563891
[TBL] [Abstract][Full Text] [Related]
9. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of combined expression of MUC1 and adhesion molecules in advanced gastric cancer.
Ohno T; Aihara R; Kamiyama Y; Mochiki E; Asao T; Kuwano H
Eur J Cancer; 2006 Jan; 42(2):256-63. PubMed ID: 16356709
[TBL] [Abstract][Full Text] [Related]
11. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
[TBL] [Abstract][Full Text] [Related]
12. Expression of MUC1 mucins in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder.
Kawamoto T; Shoda J; Irimura T; Miyahara N; Furukawa M; Ueda T; Asano T; Kano M; Koike N; Fukao K; Tanaka N; Todoroki T
Clin Cancer Res; 2001 May; 7(5):1333-42. PubMed ID: 11350903
[TBL] [Abstract][Full Text] [Related]
13. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules.
Burke PA; Gregg JP; Bakhtiar B; Beckett LA; Denardo GL; Albrecht H; De Vere White RW; De Nardo SJ
Int J Oncol; 2006 Jul; 29(1):49-55. PubMed ID: 16773184
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
15. [Factors influencing the progression-free survival time of prostate cancer patients after endocrine therapy].
Guan YB; Zhang YF; Wen H; Zhou SQ; Dai YT
Zhonghua Nan Ke Xue; 2009 Sep; 15(9):801-5. PubMed ID: 19947562
[TBL] [Abstract][Full Text] [Related]
16. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
18. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
20. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]